The tranylcypromine stereoisomers have been investigated in a series of comparative trials in Parkinson's disease and the results indicate that doses below 3 mg/day, of the (+ )-isomer in particular, are effective as adjuvant antiparkinsonian therapy. Biochemical results, monitoring platelet monoamine oxidase (MAO) activity and plasma concentrations of drugs and phenylethylamine, an MAO substrate, showed such low doses of the ( +)-isomer to inhibit MAO without inducing the hypertensive reaction sometimes observed at higher dosage. These findings, along with the observation of substantial pharmacokinetic differences between the two isomers are discussed, particularly in relation to reports on their efficacy in depressive illness.
Introduction
Tranylcypromine has been used as an effective antidepressant drug for over 20 years. Clinically it is considered by many to be the best of the antidepressant monoamine oxidase (MAO) inhibitors, although its side effects have often made its use unacceptable. However, over the past few years, there have been signs that a reassessment of tranylcypromine medication might lead to its more effective use in depression and even, perhaps, to its application in other diseases.
As employed therapeutically, tranylcypromine is a racemic mixture of two stereoisomers with substantially different biological effects. Thus, the (+ )-isomer is the stronger MAO inhibitor, both in the experimental animal (Horn & Snyder 1972) and in human brain (Reynolds et al. 1980b ) while the ( -)-isomer is the more effective inhibitor of monoamine uptake (Horn & Snyder 1972) . Since this latter effect may contribute to the antidepressant action of the tricyclic drugs, it is unclear whether this or MAO inhibition, to mention but two possibilities, is responsible for the efficacy of racemic tranylcypromine.
Our initial interest in the tranylcypromine isomers followed the successful application of another MAO inhibitor, ( -)-deprenyl, to the treatment of Parkinson's disease (Birkmayer et al. 1975 , Lees et al. 1977 ). An L-dopa-( -)-deprenyl combination permits a reduction in the total amount of L-dopa required, with a consequent decrease in some peripheral side effects. ( -)-Deprenyl is thought to act in this condition by selectively inhibiting MAO type B, which is predominantly responsible for dopamine inactivation in the human brain (Glover et al. 1977) . Our studies have, shown that the tranylcypromine isomers also exhibit, albeit to a lesser extent, a selective type B inhibition of human brain MAO (Reynolds et al. I980b ). Thus, it seemed possible that one or both of the isomers might be effective as an adjuvant antiparkinsonian agent, in combination, as before, with L-dopa.
We present here the results ofa series of studies of the biochemical and clinical effects of the tranylcypromine isomers in parkinsonian patients.
Methods
The biochemical effects of two initial trials of (+)-and (-)-tranylcypromine have previously been reported (Reynolds et al. 1980a) . These preliminary studies have been extended in two further crossover trials of the two isomers in Parkinson's disease, one of 5 mg daily for 4 days in 15 patients, the other I mg increasing to 3 mg daily over a period of two weeks in 6 patients. The preparation of samples, assay of platelet MAO and gas chromatographic determination of tranylcypromine and phenylethylamine have been described previously (Reynolds et al. 1980a ).
Results
Initial experiments showed both tranylcypromine isomers to have substantial effects, both clinically and biochemically, at dose levels less than 10 mg/day, Thus 5 mgjday was chosen in a trial with 15 parkinsonian patients. Anti-parkinsonian therapeutic effects were noted in response to both isomers; in general, the (+ )-isomer substantially improved motor performance while the ( -)-isomer was thought to alleviate psychiatric symptoms. However, a major side effect was a hypertensive response in several of the patients receiving L-dopa in addition to ( +)-tranylcypromine medication. The biochemical findings after 3 days' treatment are shown in Table I . The predicted greater degrees of MAO inhibition by the (+ )-isomer can be seen; however, raised concentrations of circulating phenylethylamine, a substrate for MAO, show that both isomers produced some degree of enzyme inhibition. Plasma and urinary concentrations of tranylcypromine demonstrated that the ( -)-form is metabolized and excreted faster than its optical isomer, as we have previously reported (Reynolds et al. 1980a ). This finding is upheld by results on samples taken 3 days after the last tranylcypromine dose; after the (+ )-isomer, tranylcypromine could still be measured in plasma and urine but after the (-)-isomer, it was not detectable.
The results of this trial prompted us to an assessment of still lower doses of the two isomers. Administration of I mg of each, or of the racemic mixture, rising to 3 mg according to clinical response, were provided daily in 6 parkinsonian patients in addition to the anti-parkinsonian therapy they were already receiving. Disease symptoms improved with each drug regimen, the improvement being greater during racemic or (+ )-tranykypromine medication, as assessed by Webster's and other rating scales (see Birkmayer & Riederer 1980) . Most notable however, was the drop in the number of side effects found during treatment with the (+ )-isomer (D Seemann and W Danielczyk, in preparation).
The corresponding biochemical results can be summarized as follows: while (-)tranylcypromine was ineffective as a platelet MAO inhibitor (less than 45% inhibition in all cases), after a week or more of treatment both the ( +j-isomer and the racemate substantially decreased platelet MAO activity by amounts (over 70%) shown to provide a functional degree of inhibition.
Discussion
It would appear from these results that low doses of ( +)-tranylcypromine are an effective anti-parkinsonian therapy which do not exhibit the side effects observed with doses of greater than 5 mg/day and indeed they have led to low doses of the drug being used routinely as antiparkinsonian therapy in the Neurological Department where these trials were carried out. It seems likely that MAO inhibition plays a part in this effect since the poorer response to (-)tranylcypromine was associated with a lesser degree of enzyme inhibition.
The hypertensive response to L-dopa during MAO inhibitor therapy is a well recognized reaction which can be subsumed under the blanket title, 'cheese effect' (Marley & Blackwell 1970) , the hypertensive reaction which follows the ingestion of noradrenaline-releasing monoamines such as tyramine, known to be present in certain foodstuffs. (-)-Deprenyl, as used in Parkinson's disease, is alone among clinically-used MAO inhibitors in exhibiting no such cheese effect (Elsworth et al. 1978) , although the reason for this is still unclear (Sandler et al. 1980) . It is, perhaps, relevant to mention that Teychenne et al. (1975) found that treatment with a peripheral decarboxylase inhibitor could, to some extent, prevent the hypertensive response to L-dopa in tranylcypromine-treated patients, confirming that the effect is predominantly a peripheral one.
In our studies, the cheese effect was found to be attenuated at lower ( +)-tranylcypromine doses and, at the 5 mg dose, it was even less prominent with the ( -)-isomer, as has been noted with higher doses by other authors (Moises & Beckmann 1981, E Ruther, in preparation) ; in . each case platelet MAO was functionally inhibited, although not to the same degree, so that it would appear that the extent of MAO inhibition, in this particular case, is more important than facilitation of amine dose (Sandler 1981) . There is, however, a further consideration; the tranylcypromine isomers are almost totally metabolized in the body and our results confirm earlier findings that the ( -)-isomer is removed more rapidly from the circulation (Lang et al. 1979 , Reynolds et al. 1980a . Thus any comparison of the clinical effects of the two drugs should take into account this pharmacokinetic difference, perhaps by separate optimization of effective drug dosage.
These different types of pharmacological action, MAO inhibition, monoamine release (or perhaps prevention of reuptake), differential drug metabolic rate, and perhaps others yet unknown, make interpretation of the action of the two isomers in another disease complex where MAO inhibitors have been employed -depressive illness -difficult to interpret. Escobar et al. (1974) studied the effects of the separate tranylcypromine isomers in depressed patients and concluded that the ( -)-form had both a better therapeutic effect and a lower incidence of side effects than ( +)-tranylcypromine, in a dosage range of 10-30 mg/day, This study has recently been criticized by Moises & Beckmann (1981) who, in their own doubleblind trial of 5-20 mg/day, found the ( +)-isomer to be a better antidepressant although it also induced more pronounced side effects. The picture is clouded, however, by another recent study (E Ruther, in preparation) where 50 mg/day of either isomer were shown to be effective, with (-)-tranylcypromine providing marginally greater benefit and (+ )-tranylcypromine again being associated with a higher incidence of side effects.
Thus, it remains unclear which isomer is the more effective antidepressant. This uncertainty presumably reflects the different methods of assessment employed, different patient populations and, perhaps most importantly, different dosage schedules used because of differences between the body's handling of the two drugs.
If the antidepressant action of tranylcypromine is due to MAO inhibition, then it would appear that a daily dose of less than 3 mg ( +)-tranylcypromine or racemate, or 5 mg/day of the (-)-isomer should be effective. On the other hand, the antidepressant effect may be
intrinsically bound up with the cheese effect itself (Mendis et al. 1981) . Further work is obviously necessary to enable us to decide between these possibilities.
